Eribulin has two major side effects and a couple other side effects that generally don't lead to dose reduction. Eribulin causes alopecia and fatigue, however not to the point with fatigue that we would go ahead with dose reduction.
Triple Negative Breast Cancer: Case 1
Christine H is a 54-year-old stay-at-home-mother who works part time as a real estate agent. Medical history is notable for hypertension (well controlled) and surgery for aortic aneurysm in 2011
In September 2013, she presented to her PCP with a right breast lump; mammogram showed a large primary breast mass and two enlarged axillary lymph nodes.
She underwent an extent of disease evaluation, which consisted of a chest, abdomen, pelvis, and bone scan, which showed no evidence of distant metastases
Ultrasound-guided core needle biopsy of the right breast mass revealed grade 3 invasive ductal carcinoma that was ER-, PgR-, and HER2- (triple-negative) with cytokeratin 5/6 staining and 50% Ki67 staining
The patient proceeded to right breast mastectomy and axillary lymph node dissection in October 2013
She had a 4.8cm invasive breast cancer and the axillary lymph node dissection showed 15 positive nodes
She underwent adjuvant therapy with doxorubicin plus cyclophosphamide (4 cycles), followed up by paclitaxel (4 cycles) and post-mastectomy radiation
At her follow-up in May 2014, the patient showed progression of the right chest wall metastases, and several new liver lesions were detected.
She underwent therapy with paclitaxel plus bevacizumab for 5 cycles and her disease stabilized
In December of 2014, she presented with increasing fatigue and chest pain on follow up and her CT scan was consistent with progression of the hepatic metastases, with several new lesions also noted in the lungs; her ECOG performance status (PS) at the time was 1.
She underwent therapy with pegylated liposomal doxorubicin and had a partial response after 4 cycles of therapy. After 6 cycles of therapy, she experienced progression
Her CBC, liver, and kidney function at the time of progression were within normal limits
Her oncologist initiated therapy with eribulin mesylate (1.4 mg/m2 IV on days 1 and 8 of a 21-day cycle)
She experienced a partial response. Dose was reduced to 1.1 mg/m2 after she developed grade 3 peripheral neuropathy
Her condition improved at the reduced dose and she continues in remission after 4 cycles